Turoctocog Alfa Pegol
Turoctocog alfa pegol (N8-GP) is a PEGylated recombinant factor VIII product where glycoPEGylation extends the half-life of the molecule compared to standard recombinant factor VIII, enabling less frequent dosing for hemophilia A prophylaxis. The glycoPEGylation via O-glycan attachment reduces renal clearance and extends circulatory half-life to approximately 19 hours. It allows once-weekly or less frequent prophylactic dosing while maintaining hemostatic efficacy.
Wirkmechanismus
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
Turoctocog alfa pegol (N8-GP) is a PEGylated recombinant factor VIII product where glycoPEGylation extends the half-life of the molecule compared to standard recombinant factor VIII, enabling less frequent dosing for hemophilia A prophylaxis. The glycoPEGylation via O-glycan attachment reduces renal clearance and extends circulatory half-life to approximately 19 hours. It allows once-weekly or less frequent prophylactic dosing while maintaining hemostatic efficacy.
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Yes, Turoctocog Alfa Pegol is an approved drug. It has reached clinical phase 4. It is classified as a Protein.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5315071. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="turoctocog-alfa-pegol"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/turoctocog-alfa-pegol/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/turoctocog-alfa-pegol/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/turoctocog-alfa-pegol/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="turoctocog-alfa-pegol"></drugfyi-drug>